6 September 15 2008 EACTS Daily News Surgery, Medical School, Kiel, Germany; University of Wisconsin Department of Cardiothoracic Surgery, Kimberly-Clark InteguSeal* microbial sealant gical equipment, instruments and sup- plies category of the MDEA competi- wins medical design excellence award Medical School, Madison, Wisconsin, USA tion. Invited Discussant: T Walther, Leipzig “We are honoured and delighted to 10:15 Mechanisms of failure of aortic valve repair: an be recognized by the MDEA judges for I intraoperative transoesophageal nteguSeal*, the innovative microbial vative use of materials, user-related InteguSeal* Microbial Sealant,” said echocardiographic study sealant from Kimberly-Clark Health functions that improve health care Kimberly-Clark Vice President of Global J-B Le Polain de Waroux; A-C Pouleur; A Pasquet; Care, has been singled out for a pres- delivery and change traditional med- Sales and Marketing John Amat. “This M Van Dyck; P Noirhomme; J-L J Vanoverschelde; tigious medical design excellence ical attitudes or practices, features award recognizes the important work G El Khoury award. that provide enhanced benefits to the that medical device companies are Cliniques Universitaires, St Luc Universite Designed to reduce the risk of skin patient and the ability of the product doing to advance the design and func- Catholique de Louvain, Brussels, Belgium Invited Discussant: M J Antunes, Coimbra flora contamination throughout a surgi- development team to overcome tionality of products that contribute to cal procedure, design and engineering challenges so improved patient outcomes and aid Auditorium 3&4 Session 6 InteguSeal* Microbial Sealant Excellence Awards (MDEA) competi- the product meets its clinical objec- medical professionals on the front lines Thymus Chairmen: L Spaggiari, Milan (www.integuseal.com) uses a propri- tion is organized and presented by tives. of delivering care.” P Van Schil, Antwerp etary formulation to seal and immobi- Canon Communications LLC (Los A comprehensive review of the The 2008 Medical Design Excellence 09:30 Clinical outcomes of video-assisted lize pathogens to help protect against Angeles) and is the only awards pro- entries was performed by a multidiscipli- Award winners were honoured at a thoracoscopic surgery (vats) for thymomas migration into an incision. To date, gram that exclusively recognizes con- nary panel of third-party jurors with ceremony during the Medical Design & A Thirugnanam 1; J L Soon 2 InteguSeal* has been used in more tributions and advances in the design expertise in biomedical engineering, Manufacturing (MD&M) East 1 National Cancer Center, Singapore; than 150,000 applications during surgi- of medical products. Entries are evalu- human factors, industrial design, medi- Conference and Exposition, June 3–5, 2 National Heart Center, Singapore cal procedures across the world. ated on the basis of their design and cine and diagnostics. InteguSeal* 2008, at New York City’s Jacob K. Javits 09:42 Plasmapheresis before thymectomy in The US-based 2008 Medical Design engineering features, including inno- received the top gold award in the sur- Convention Center. myasthenia gravis: routine vs. Selective protocols K Al-Kattan1; H El-Bawab1; W Hajjar 2; M Rafay1; A Bamousa1; A Khalil1 Does pretransplant LVAD support improve pared to direct transplantation in patients with ele- vated PVR. 1 King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; results after heart transplantation in All heart transplant recipients at Sahlgrenska University Hospital, Gothenburg, during the period 2 King Khalid University Hospital, Riyadh, Saudi Arabia patients with elevated PVR? 1988-2007 with pretransplant PHT were divided into two groups. Group 1 were patients without LVAD 09:54 Association of thymoma and myasthenia gravis: O oncological and neurological results of surgical rthothopic heart transplantation is the gold of death after cardiac treatment (n=58) and group 2 patients treated with treatment standard for patients with terminal heart fail- transplantation and PVR LVAD prior to transplant (n=11). M Lucchi; F Melfi; P Dini; F Davini; L Duranti; ure. Progress in the underlying disease leads to < 5 WU is regarded as a Group 1 had a mean pretransplant PVR of 3.2 ± A Viti; A Mussi backward failure and changes in the pulmonary circu- contraindication for heart 0.7. Group 2 had a mean pretransplant PVR of 3.2 ± Azienda Ospedaliera Universitaria Pisana, Pisa, Italy lation, eventually leading to decreased right ventricu- transplantation. Recently 0.9 that was reduced to 2.1 ± 0.6 after LVAD treat- 10:06 Early masaoka stage and complete resection is lar function. Remodelling of the pulmonary vascula- it has been shown that ment. Two cases of acute right heart failure after important for the prognosis of thymic ture occurs quickly, at first reversible, but at some circulatory support with a transplantation required mechanical support in group carcinoma: from the 20-year experience of a point becoming irreversible, resulting in a fixed pul- left ventricular assist 1. None of the patients in group 2 developed periop- single institution monary vascular resistance (PVR). However, an device (LVAD) can reduce erative right heart failure requiring mechanical sup- C Y Lee; I K Park; M K Bae; K Chung absolute cut-off value of PVR does not exist. The right the resistance in the pul- port. The incidence of other perioperative complica- Department of Thoracic and Cardiovascular Surgery ventricle of the donor heart tolerates increased PVR monary vasculature. It tions was comparable between the two groups. Four- Yonsei University College of Medicine, Seoul, Korea poorly, resulting in acute perioperative right-sided fail- has furthermore been year survival in group 1 and 2 was 70% and 63 %, (South) ure, which can be difficult to manage pharmacologi- shown that transplanted Lars Wiklund respectively. 10:18 Long-term outcome of extended thoracoscopic thymectomy for nonthymomatous myasthenia cally. After heart transplantation in patients with ele- patients with elevated PVR Pretransplant LVAD treatment reduced the pul- gravis vated PVR, the majority of survivors will normalize pre-treated with LVAD have as good a survival as monary pressure in heart transplant recipients with E Pompeo; F Tacconi; R Massa; their PVR which questions the irreversibility of elevat- patients with normal PVR. After those important find- PHT but there was no statistically significant differ- G Bernardi; T C Mineo ed resistance. ings we now consider pretransplant LVAD implantation ence in short-term survival in patients treated with or Department of Thoracic Surgery, Policlinico Tor Pulmonary hypertension (PHT) is a risk factor for to be indicated rather than contraindicated in patients without LVAD. The relatively good results in patients Vergata University, Rome, Italy early and late death after heart transplantation. There is with elevated PVR. with elevated PVR and no prior LVAD treatment can Auditorium 2 Session 7 a consensus that PVR < 2.5 Wood units (WU) and The purpose of this study was to determine the be accredited early and powerful pharmaceutical resistant to pharmacologic dilatation increases the risk outcome of pretransplant treatment with LVAD com- treatment of right heart failure.
Pages to are hidden for
"Kimberly-Clark InteguSeal microbial sealant wins medical design"Please download to view full document